Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HPD | P32754 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129420 | 0.90 | L3MBTL1 (0.55) | L3MBTL1LMNAMAPTGAAMEN1 | |
| SCHEMBL1129529 | 0.88 | MAPT (0.52) | L3MBTL1LMNAMAPTMEN1KMT2A | |
| SCHEMBL1129588 | 0.86 | L3MBTL1 (0.68) | L3MBTL1LMNAMAPTMEN1KMT2A | |
| SCHEMBL1129814 | 0.85 | NTSR1 (0.49) | L3MBTL1LMNAMAPTMEN1KMT2A | |
| SCHEMBL18230980 | 0.81 | HTT (0.49) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL1129573 | 0.81 | APLNR (0.61) | L3MBTL1LMNAMAPTGAATP53 | |
| SCHEMBL9670132 | 0.80 | POLB (0.57) | ALDH1A1POLB | |
| SCHEMBL9671395 | 0.78 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1POLB | |
| SCHEMBL1129305 | 0.77 | HPGD (0.50) | L3MBTL1LMNAMAPTMEN1KMT2A | |
| SCHEMBL1129587 | 0.77 | PIK3CG (0.51) | L3MBTL1LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283151-B1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET | F2G LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-9034887-B2 | Dihydroorotate dehydrogenase as antifungal drug target and quinazolinone-based inhibitors thereof | F2G LIMITED (GB) | 2015-05-19 | — | — | US | disclosed |
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| EP-2283151-A2 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009133379-A2 | ANTIFUNGAL TARGET | F2G LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160231-A1 | DIHYDROOROTATE DEHYDROGENASE AS ANTIFUNGAL DRUG TARGET AND QUINAZOLINONE-BASED INHIBITORS THEREOF | DHODH, DHRS9, DLD | L3MBTL1 4206/4885LMNA 4570/4885MAPT 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.